Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of …
Summary Background RTS, S/AS02A is a pre-erythrocytic stage malaria vaccine that
provides partial protection against infection in malaria-naive adult volunteers and …
provides partial protection against infection in malaria-naive adult volunteers and …
Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised …
KP Asante, S Abdulla, S Agnandji, J Lyimo… - The Lancet infectious …, 2011 - thelancet.com
Summary Background The RTS, S/AS01 E candidate malaria vaccine is being developed for
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …
immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 …
Safety and immunogenicity of the RTS, S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique
E Macete, JJ Aponte, C Guinovart… - Tropical Medicine & …, 2007 - Wiley Online Library
Background The development of a malaria vaccine remains a public health priority for sub‐
Saharan Africa. RTS, S/AS02A candidate malaria vaccine has been shown to be safe and …
Saharan Africa. RTS, S/AS02A candidate malaria vaccine has been shown to be safe and …
Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS, S/AS02 in Mozambique
JJ Campo, J Sacarlal, JJ Aponte, P Aide… - Vaccine, 2014 - Elsevier
A primary concern for the RTS, S malaria vaccine candidate is duration of protection. The
ongoing Phase III trial reported evidence of waning efficacy within the first year following …
ongoing Phase III trial reported evidence of waning efficacy within the first year following …
European Medicines Agency approves first malaria vaccine
N Hawkes - 2015 - bmj.com
A vaccine against malaria has gained regulatory approval for the first time. Mosquirix,
developed by GlaxoSmithKline, has been approved by the European Medicines Agency …
developed by GlaxoSmithKline, has been approved by the European Medicines Agency …
Safety and immunogenicty of RTS, S/AS02A candidate malaria vaccine in Gambian children
KA Bojang, F Olodude, M Pinder, O Ofori-Anyinam… - Vaccine, 2005 - Elsevier
RTS, S/AS02A is a pre-erythrocytic malaria vaccine candidate in which a portion of the
circumsporozoite surface protein (CSP) of Plasmodium falciparum is genetically linked to …
circumsporozoite surface protein (CSP) of Plasmodium falciparum is genetically linked to …
RTS, S/AS01 malaria vaccine efficacy is not modified by seasonal precipitation: results from a phase 3 randomized controlled trial in Malawi
Abstract The World Health Organization has selected Malawi as one of three sites to pilot the
roll-out of RTS, S/AS01 in phase 4 trials. As policy discussions for the expanded use of RTS …
roll-out of RTS, S/AS01 in phase 4 trials. As policy discussions for the expanded use of RTS …
The development of the RTS, S malaria vaccine candidate: challenges and lessons
WR Ballou - Parasite immunology, 2009 - Wiley Online Library
RTS, S is the world's most advanced malaria vaccine candidate and is intended to protect
infants and young children living in malaria endemic areas of sub‐Saharan Africa against …
infants and young children living in malaria endemic areas of sub‐Saharan Africa against …
[HTML][HTML] Routine malaria vaccinations start in Africa
P Venkatesan - The Lancet Microbe, 2024 - thelancet.com
Malaria vaccines are being introduced into routine child immunisation schedules in Africa in
2024. Other prevention measures such as mosquito bednets and insecticides must continue …
2024. Other prevention measures such as mosquito bednets and insecticides must continue …